Skip to main content

03-06-2022 | ASCO 2022 | Conference coverage | Video

COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity


Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer (2:11).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

2022 ASCO Annual Meeting coverage

Access the latest news and expert insight from the 2022 ASCO Annual Meeting